Introduction:
The biologics market in the United States is experiencing significant growth, driven by factors such as an aging population and increasing prevalence of chronic diseases. According to market research, the global biologics market is expected to reach $479.7 billion by 2026, with the United States accounting for a significant portion of this revenue. In this report, we will explore the top 10 biologics consumer behaviors in the United States in 2026.
Top 10 Biologics Consumer Behavior in United States 2026:
1. Humira (AbbVie): With over $20 billion in global sales, Humira continues to be the top-selling biologic in the United States. Its success can be attributed to its effectiveness in treating autoimmune diseases such as rheumatoid arthritis and psoriasis.
2. Keytruda (Merck): Keytruda is a leading biologic in the United States, with sales exceeding $11 billion in 2026. This immunotherapy drug is widely used in the treatment of various types of cancer, including lung cancer and melanoma.
3. Enbrel (Amgen): Enbrel remains a popular biologic in the United States, generating over $7 billion in sales. It is primarily prescribed for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriatic arthritis.
4. Rituxan (Roche): Rituxan is a widely used biologic in the United States, with sales reaching $6 billion in 2026. It is commonly prescribed for the treatment of non-Hodgkin’s lymphoma and rheumatoid arthritis.
5. Herceptin (Roche): Herceptin is a top-selling biologic in the United States, with sales surpassing $5 billion. It is primarily used in the treatment of HER2-positive breast cancer.
6. Remicade (Johnson & Johnson): Remicade is a popular biologic in the United States, generating over $4 billion in sales. It is commonly prescribed for the treatment of autoimmune diseases such as Crohn’s disease and rheumatoid arthritis.
7. Avastin (Roche): Avastin is a leading biologic in the United States, with sales exceeding $3 billion. It is widely used in the treatment of various types of cancer, including colorectal cancer and lung cancer.
8. Neulasta (Amgen): Neulasta remains a top-selling biologic in the United States, with sales reaching $2.5 billion. It is commonly prescribed to prevent infections in cancer patients undergoing chemotherapy.
9. Xolair (Novartis): Xolair is a popular biologic in the United States, generating over $2 billion in sales. It is primarily used in the treatment of allergic asthma and chronic idiopathic urticaria.
10. Stelara (Johnson & Johnson): Stelara is a successful biologic in the United States, with sales exceeding $1.5 billion. It is commonly prescribed for the treatment of psoriasis and psoriatic arthritis.
Insights:
Looking ahead to the future of biologics consumer behavior in the United States, it is clear that the market will continue to grow at a rapid pace. With advancements in biotechnology and an increasing focus on personalized medicine, we can expect to see the development of innovative biologics that target specific patient populations. Additionally, the rise of biosimilars will create opportunities for cost savings and increased access to biologic therapies. Overall, the United States remains a key market for biologics, with significant potential for growth in the coming years.
Related Analysis: View Previous Industry Report
